公开(公告)号：US20190300530A1

公开(公告)日：2019-10-03

申请号：US16383382

申请日：2019-04-12

Applicant: Novartis AG

Inventor： Jiping FU ,  Wooseok HAN ,  Subramanian KARUR ,  Peichao LU ,  Keith Bruce PFISTER ,  Joseph Michael YOUNG

IPC: C07D471/14 ,  C07D401/12 ,  C07D491/16 ,  A61P31/12 ,  A61K45/06 ,  C07D471/22 ,  A61K31/4985 ,  C07D405/12

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20180030053A1

公开(公告)日：2018-02-01

申请号：US15782722

申请日：2017-10-12

Applicant: Novartis AG

Inventor： Jiping FU ,  Xianming JIN ,  Patrick LEE ,  Peichao LU ,  Joseph Michael YOUNG

IPC: C07D471/14 ,  C07D491/147 ,  A61K31/4375

CPC classification number: C07D471/14 ,  A61K31/4375 ,  C07D217/08 ,  C07D491/14 ,  C07D491/147

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20170174640A1

公开(公告)日：2017-06-22

申请号：US15454187

申请日：2017-03-09

Applicant: Novartis AG

Inventor： Jiping FU ,  Xianming JIN ,  Subramanian KARUR ,  Guillaume LAPOINTE ,  Patrick LEE ,  Zachary Kevin SWEENEY

IPC: C07D261/04 ,  C07D413/04 ,  A61K31/4439 ,  A61K45/06 ,  A61K31/5377 ,  C07D417/10 ,  A61K31/427 ,  A61K31/422 ,  A61K31/42 ,  C07D413/10

CPC classification number: C07D261/04 ,  A61K31/42 ,  A61K31/421 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/5377 ,  A61K45/06 ,  C07D413/04 ,  C07D413/10 ,  C07D417/10

Abstract: This invention pertains generally to compounds of Formula I and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention pertains to methods and compositions for treating infections caused by Gram-negative bacteria.

公开(公告)号：US20210346377A1

公开(公告)日：2021-11-11

申请号：US16956527

申请日：2018-12-19

Applicant: Novartis AG

Inventor： Jiping FU ,  Wooseok HAN ,  Xianming JIN ,  Keith Bruce PFISTER ,  Joseph Michael YOUNG

IPC: A61K31/4985 ,  C07D471/14 ,  A01N43/90 ,  A61K45/06 ,  A61K47/60 ,  A61K38/21 ,  A61P31/20

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20180312507A1

公开(公告)日：2018-11-01

申请号：US15965172

申请日：2018-04-27

Applicant: Novartis AG

Inventor： Jiping FU ,  Wooseok HAN ,  Subramanian KARUR ,  Peichao LU ,  Keith Bruce PFISTER ,  Joseph Michael YOUNG

IPC: C07D471/14 ,  C07D405/12 ,  C07D401/12 ,  C07D491/16 ,  A61P31/12

CPC classification number: C07D471/14 ,  A61K31/4985 ,  A61K45/06 ,  A61P31/12 ,  C07D401/12 ,  C07D405/12 ,  C07D471/22 ,  C07D491/16

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20170355684A1

公开(公告)日：2017-12-14

申请号：US15620373

申请日：2017-06-12

Applicant: Novartis AG

Inventor： Jiping FU ,  Siyi JIANG ,  Andreas KORDIKOWSKI ,  Zachary Kevin SWEENEY

IPC: C07D261/08 ,  A61K31/7048 ,  A61K38/14 ,  A61K31/42 ,  A61K38/12 ,  A61K31/431 ,  A61K31/65 ,  A61K31/7036 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/546 ,  A61K31/43

CPC classification number: C07D261/08 ,  A61K31/42 ,  A61K31/43 ,  A61K31/431 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/546 ,  A61K31/65 ,  A61K31/7036 ,  A61K31/7048 ,  A61K38/12 ,  A61K38/14 ,  C07B2200/13

Abstract: This invention pertains to a crystalline compound of Formula (A) as described herein and compositions containing this crystalline compound, as well as methods of using the compound or pharmaceutical compositions comprising it to treat bacterial infections. The compound and compositions are especially useful to treat Gram negative bacterial infections, including multi-drug resistant strains.

公开(公告)号：US20210079015A1

公开(公告)日：2021-03-18

申请号：US16764525

申请日：2018-11-16

Applicant: Novartis AG

Inventor： Jiping FU ,  Mika LINDVALL ,  James R. MANNING ,  Glenn MCENROE

IPC: C07D498/04

Abstract: The invention provides compounds of Formula (I) n R3b Z W Q R3a H Y N R1 R4 R2 O (I) as described herein, along with stereoisomeric forms salts, hydrates, solvates, and salts thereof and pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20170240548A1

公开(公告)日：2017-08-24

申请号：US15435137

申请日：2017-02-16

Applicant: Novartis AG

Inventor： Jiping FU ,  Xianming JIN ,  Patrick LEE ,  Peichao LU ,  Joseph Michael YOUNG

IPC: C07D471/14 ,  C07D491/147 ,  A61K31/4375

CPC classification number: C07D471/14 ,  A61K31/4375 ,  C07D217/08 ,  C07D491/14 ,  C07D491/147

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20170088525A1

公开(公告)日：2017-03-30

申请号：US15375560

申请日：2016-12-12

Applicant: Novartis AG

Inventor： Jiping FU ,  Xianming JIN ,  Subramanian KARUR ,  Guillaume LAPOINTE ,  Ann Marie MADERA ,  Zachary Kevin SWEENEY

IPC: C07D261/08 ,  A61K31/42 ,  A61K45/06

CPC classification number: C07D261/08 ,  A61K31/42 ,  A61K31/422 ,  A61K45/06 ,  C07D413/06 ,  C07D413/12 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/481 ,  A61K2300/00

Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.

公开(公告)号：US20200270265A1

公开(公告)日：2020-08-27

申请号：US15999664

申请日：2017-02-16

Applicant: Novartis AG

Inventor： Jiping FU ,  Xianming JIN ,  Patrick LEE ,  Peichao LU ,  Joseph Michael YOUNG

IPC: C07D491/147 ,  C07D471/04 ,  C07D519/00 ,  A61P31/20

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.